<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077711</url>
  </required_header>
  <id_info>
    <org_study_id>EH16-216</org_study_id>
    <nct_id>NCT03077711</nct_id>
  </id_info>
  <brief_title>Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs</brief_title>
  <official_title>Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthShore University HealthSystem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several methods are available for use in the prevention of recurrent urinary tract infections
      (UTIs) over the past few decades. These methods include suppressive antibiotics, estrogen
      cream, methenamine hippurate, d-mannose, cranberry, probiotics, and vitamin C. Of these, the
      majority of the literature is in favor of use of suppressive antibiotics for preventing UTIs.
      However, this data is now about 10 years old. Increasing use of antibiotics over the years
      has lead to increased resistance of bacteria. In addition, long-term antibiotic use has
      several adverse effects, some life-threatening. There is recent literature evaluating the use
      of several of the alternatives to suppressive antibiotics with mixed results. A comparative
      study of the efficacy of methenamine hippurate to suppressive antibiotics is lacking in the
      current literature. Several early partly-randomized trials done with methenamine hippurate
      have shown promising results, but are only as recent as 1987. The primary objective of this
      prospective, randomized study is to determine whether there is a significant difference in
      the prevention of recurrent UTIs when given either methenamine hippurate or daily suppressive
      antibiotics. The secondary objective of this study is to determine how well patients are able
      to tolerate each of these medications and what adverse effects are observed in a given 1 year
      time period. The long-term goals of this study are to find an alternative to using
      suppressive antibiotics, potentially with a lower adverse effect profile and less of the
      dangers of long term antibiotic use. Finding an alternative to suppressive antibiotics would
      also tackle the issue of antibiotic resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:

      The hypothesis of this study is that the group taking trimethoprim will have a lower
      recurrence rate than those taking methenamine hippurate based on the literature. The
      investigators aim to identify to what degree that difference is and whether or not it is an
      acceptable difference given the greater degree of an antibiotic resistance.

      Objectives:

      The primary objective of this prospective, randomized study is to determine whether there is
      a significant difference in the prevention of recurrent UTIs when given either methenamine
      hippurate or daily suppressive antibiotics independent of vaginal estrogen use.

      The secondary objective of this study is to determine how well patients are able to tolerate
      each of these medications and what adverse effects are observed in a 1 year time period.

      Specific Aims:

        1. Identify if there is a differential impact on prevention of recurrent UTIs when treated
           with either trimethoprim or methenamine hippurate in a 6 and 12 month period.

        2. Identify adverse reactions in each group.

        3. Determine whether or not estrogen has a more additive effect to trimethoprim or
           methenamine hippurate in post-menopausal women.

        4. Identify how well tolerated the study medications are and whether or not the size of the
           pills or the frequency of taking them prevents patients from continuing therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 21, 2019</completion_date>
  <primary_completion_date type="Actual">June 21, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients diagnosed with recurrent urinary tract infections are recruited into this study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Patients will be advised to follow up with any symptoms of a recurrence or at 6 and 12 month intervals if symptom-free.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent UTI</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The number of patient who had a recurrence of UTI within 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infections</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The number of infections at a 12 month follow up time period as defined by symptoms and positive urine culture.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The percentage of patients complaining of adverse effects of each medication, including dyspepsia, dysuria, rash, pruritus, nausea, epigastric pain, vomiting, glossitis, taste changes, fever, and photosensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morisky Medication Adherence Survey</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Morisky Medication Adherence Scale-8 (MMAS-8). Patient tolerability of medications using a tolerability survey. Minimum and maximum scores are 0 and 8 respectively. 0 means no adherence and 8 is maximal adherence. Low adherence corresponds to a score less than 6, medium adherence is between 6 and &lt;8, and 8 is high adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial Infection Prevalence and Types</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Urine cultures and sensitivities for positive urine cultures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Urinary Tract Infections, Recurrent</condition>
  <arm_group>
    <arm_group_label>Patients with recurrent UTIs arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with recurrent UTIs arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
    <description>suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).</description>
    <arm_group_label>Patients with recurrent UTIs arm 2</arm_group_label>
    <other_name>Trimpex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methenamine hippurate</intervention_name>
    <description>antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).</description>
    <arm_group_label>Patients with recurrent UTIs arm 1</arm_group_label>
    <other_name>Hiprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent UTI: at least 2 in the past 6 months or 3 in past year (culture positive)

          -  must have been symptomatic with dysuria, urgency, frequency, suprapubic pain,
             hematuria, malodorous urine

          -  treated for last UTI and negative urine culture on entry into study

          -  English speaking

        Exclusion Criteria:

          -  pregnancy

          -  urinary tract abnormalities (eg kidney stones)

          -  acute pyelonephritis

          -  renal insufficiency or failure

          -  known allergy to medications

          -  prophylaxis for post-coital recurrent UTIs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NorthShore Univeristy HealthSystem</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <results_first_submitted>December 12, 2019</results_first_submitted>
  <results_first_submitted_qc>January 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2020</results_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem</investigator_affiliation>
    <investigator_full_name>Carolyn Botros</investigator_full_name>
    <investigator_title>Female Pelvic Medicine and Reconstructive Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Methenamine</mesh_term>
    <mesh_term>Methenamine hippurate</mesh_term>
    <mesh_term>Methenamine mandelate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators are currently only recruiting at one institution and only researchers on the original institutional review board will have access to data. Only the principal investigator and research coordinator will have the data to be analyzed.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03077711/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>104 patients actually signed consent to participate but 12 were excluded due to screening failure, decision to decline participation after signing consent, renal failure discovered after enrolling patient, and one unrelated death</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With Recurrent UTIs Arm 1</title>
          <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent urinary tract infections (UTIs).</description>
        </group>
        <group group_id="P2">
          <title>Patients With Recurrent UTIs Arm 2</title>
          <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections (UTIs).
Trimethoprim: suppressive antibiotic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>noncompliant taking medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Recurrent UTIs Arm 1</title>
          <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).</description>
        </group>
        <group group_id="B2">
          <title>Patients With Recurrent UTIs Arm 2</title>
          <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="15.4"/>
                    <measurement group_id="B2" value="73" spread="10.5"/>
                    <measurement group_id="B3" value="72" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="6.4"/>
                    <measurement group_id="B2" value="30" spread="7.7"/>
                    <measurement group_id="B3" value="30" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>number of births</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="2.2"/>
                    <measurement group_id="B2" value="2.3" spread="1.4"/>
                    <measurement group_id="B3" value="2.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI</title>
        <description>Patients will be advised to follow up with any symptoms of a recurrence or at 6 and 12 month intervals if symptom-free.</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Recurrent UTIs Arm 1</title>
            <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs.</description>
          </group>
          <group group_id="O2">
            <title>Patients With Recurrent UTIs Arm 2</title>
            <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI</title>
          <description>Patients will be advised to follow up with any symptoms of a recurrence or at 6 and 12 month intervals if symptom-free.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="84.4"/>
                    <measurement group_id="O2" value="119" spread="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recurrent UTI</title>
        <description>The number of patient who had a recurrence of UTI within 12 months</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Recurrent UTIs Arm 1</title>
            <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs.</description>
          </group>
          <group group_id="O2">
            <title>Patients With Recurrent UTIs Arm 2</title>
            <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent UTI</title>
          <description>The number of patient who had a recurrence of UTI within 12 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infections</title>
        <description>The number of infections at a 12 month follow up time period as defined by symptoms and positive urine culture.</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Recurrent UTIs Arm 1</title>
            <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs.</description>
          </group>
          <group group_id="O2">
            <title>Patients With Recurrent UTIs Arm 2</title>
            <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infections</title>
          <description>The number of infections at a 12 month follow up time period as defined by symptoms and positive urine culture.</description>
          <units>urinary tract infections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.7"/>
                    <measurement group_id="O2" value="1.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>The percentage of patients complaining of adverse effects of each medication, including dyspepsia, dysuria, rash, pruritus, nausea, epigastric pain, vomiting, glossitis, taste changes, fever, and photosensitivity.</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Recurrent UTIs Arm 1</title>
            <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs.</description>
          </group>
          <group group_id="O2">
            <title>Patients With Recurrent UTIs Arm 2</title>
            <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>The percentage of patients complaining of adverse effects of each medication, including dyspepsia, dysuria, rash, pruritus, nausea, epigastric pain, vomiting, glossitis, taste changes, fever, and photosensitivity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>rash</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>clostridium difficele infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>abdominal pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>kidney stone</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morisky Medication Adherence Survey</title>
        <description>Morisky Medication Adherence Scale-8 (MMAS-8). Patient tolerability of medications using a tolerability survey. Minimum and maximum scores are 0 and 8 respectively. 0 means no adherence and 8 is maximal adherence. Low adherence corresponds to a score less than 6, medium adherence is between 6 and &lt;8, and 8 is high adherence.</description>
        <time_frame>up to 12 months</time_frame>
        <population>We were not able to obtain the Morisky medication survey on all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Recurrent UTIs Arm 1</title>
            <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs.</description>
          </group>
          <group group_id="O2">
            <title>Patients With Recurrent UTIs Arm 2</title>
            <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>Morisky Medication Adherence Survey</title>
          <description>Morisky Medication Adherence Scale-8 (MMAS-8). Patient tolerability of medications using a tolerability survey. Minimum and maximum scores are 0 and 8 respectively. 0 means no adherence and 8 is maximal adherence. Low adherence corresponds to a score less than 6, medium adherence is between 6 and &lt;8, and 8 is high adherence.</description>
          <population>We were not able to obtain the Morisky medication survey on all participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" spread="1.1"/>
                    <measurement group_id="O2" value="6.94" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacterial Infection Prevalence and Types</title>
        <description>Urine cultures and sensitivities for positive urine cultures</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Recurrent UTIs Arm 1</title>
            <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent urinary tract infections (UTIs).</description>
          </group>
          <group group_id="O2">
            <title>Patients With Recurrent UTIs Arm 2</title>
            <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections (UTIs).
Trimethoprim: suppressive antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Infection Prevalence and Types</title>
          <description>Urine cultures and sensitivities for positive urine cultures</description>
          <units>infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterococcus faecalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended spectrum beta lactamase Escherichia coli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strains pan sensitive to all antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strains resistant to trimethoprim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strains resistant to abx other than trimethoprim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 1 year from entry into the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With Recurrent UTIs Arm 1</title>
          <description>Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
Methenamine hippurate: antiseptic used in the prevention of recurrent UTIs.</description>
        </group>
        <group group_id="E2">
          <title>Patients With Recurrent UTIs Arm 2</title>
          <description>Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
Trimethoprim: suppressive antibiotic.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>clostridium difficele colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carolyn Botros, DO</name_or_title>
      <organization>Lehigh Valley Health Network</organization>
      <phone>4845917480</phone>
      <email>carolyn.botros@lvhn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

